{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:25:02Z","timestamp":1782962702158,"version":"3.54.5"},"reference-count":34,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej20-0016","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T22:03:47Z","timestamp":1585778627000},"page":"751-758","source":"Crossref","is-referenced-by-count":6,"title":["Clinical experience of treating Graves\u2019 hyperthyroidism complicated with malignancy\u2014The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia"],"prefix":"10.1507","volume":"67","author":[{"given":"Ken","family":"Okamura","sequence":"first","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Bandai","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 Hartmann K (2015) Thyroid disorders in the oncology patient. J Adv Pract Oncol 6: 99\u2013106."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, et al. (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124: 1111\u20131121.","DOI":"10.1002\/cncr.31200"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Azmat U, Liebner D, Joehlin-Price A, Agrawal A, Nabhan F (2016) Treatment of ipilimumab induced Graves\u2019 disease in a patient with metastatic melanoma. Case Rep Endocrinol 2016: 2087525.","DOI":"10.1155\/2016\/2087525"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164: 303\u2013307.","DOI":"10.1530\/EJE-10-0833"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343\u20131421.","DOI":"10.1089\/thy.2016.0229"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Cooper DS (2005) Antithyroid drugs. N Engl J Med 352: 905\u2013917.","DOI":"10.1056\/NEJMra042972"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, et al. (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves\u2019 disease. J Clin Endocrinol Metab 97: E49\u2013E53.","DOI":"10.1210\/jc.2011-2221"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Nakamura H, Miyauchi A, Miyawaki N, Imagawa J (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 98: 4776\u20134783.","DOI":"10.1210\/jc.2013-2569"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, et al. (2016) Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 26: 627\u2013633.","DOI":"10.1089\/thy.2015.0439"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Baldini M, Gambini D, Airaghi L, Tomirotti M, Cappellini MD (2014) Remission of autoimmune hyperthyroidism after chemotherapy for cancer. Intern Emerg Med 9: 109\u2013111.","DOI":"10.1007\/s11739-013-0937-7"},{"key":"11","unstructured":"11 Plummer HS (1923) Results of administering iodine to patients having exophthalmic goiter. J Am Med Assoc 80: 1955."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Thompson WO, Thompson PK, Brailey AG, Cohen AC (1930) Prolonged treatment of exophthalmic goiter by iodine alone. Arch Intern Med 45: 481\u2013502.","DOI":"10.1001\/archinte.1930.00140100003001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Volpe R, Johnston MW (1962) The effects of small doses of stable iodine in patients with hyperthyroidism. Ann Intern Med 56: 577\u2013589.","DOI":"10.7326\/0003-4819-56-4-577"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Emerson CH, Anderson AJ, Howard WJ, Utiger RD (1975) Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40: 33\u201336.","DOI":"10.1210\/jcem-40-1-33"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Feek CM, Sawers JS, Irvine WJ, Beckett GJ, Ratcliffe WA, et al. (1980) Combination of potassium iodide and propranolol in preparation of patients with Graves\u2019 disease for thyroid surgery. N Engl J Med 302: 883\u2013885.","DOI":"10.1056\/NEJM198004173021602"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Roti E, Robuschi G, Manfredi A, D\u2019Amato L, Gardini E, et al. (1985) Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves\u2019 disease. Clin Endocrinol (Oxf) 22: 489\u2013496.","DOI":"10.1111\/j.1365-2265.1985.tb00148.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Shen DC, Wu SY, Chopra IJ, Huang HW, Shian LR, et al. (1985) Long term treatment of Graves\u2019 hyperthyroidism with sodium ipodate. J Clin Endocrinol Metab 61: 723\u2013727.","DOI":"10.1210\/jcem-61-4-723"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Philippou G, Koutras DA, Piperingos G, Souvatzoglou A, Moulopoulos SD (1992) The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf) 36: 573\u2013578.","DOI":"10.1111\/j.1365-2265.1992.tb02267.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Fontanilla JC, Schneider AB, Same DH (2001) The use of oral radiographic contrast agents in the management of hyperthyroidism. Thyroid 11: 561\u2013567.","DOI":"10.1089\/105072501750302868"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, et al. (2014) Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab 99: 3995\u20134002.","DOI":"10.1210\/jc.2013-4466"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kuroda T, Okamura K, Sato K, Inokuchi K, Mizokami T, et al. (1996) Acute exacerbation of masked hyperthyroidism after iodine restriction followed by thyrotoxic atrial fibrillation and cerebral embolism. A case report. Angiology 47: 709\u2013712.","DOI":"10.1177\/000331979604700712"},{"key":"22","unstructured":"22 Ingbar SH (1972) Autoregulation of the thyroid. Response to iodide excess and depletion. Mayo Clin Proc 47: 814\u2013823."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, et al. (1989) Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 35: 1949\u20131954.","DOI":"10.1093\/clinchem\/35.9.1949"},{"key":"24","unstructured":"24 Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N (1996) Changes in thyroid volume in response to radioactive iodine for Graves\u2019 hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 81: 3257\u20133260."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Okamura K, Sato K, Ikenoue H, Yoshinari M, Nakagawa M, et al. (1988) Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. J Clin Endocrinol Metab 67: 720\u2013726.","DOI":"10.1210\/jcem-67-4-720"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Shiroozu A, Okamura K, Ikenoue H, Sato K, Nakashima T, et al. (1986) Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 63: 125\u2013128.","DOI":"10.1210\/jcem-63-1-125"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Okamura K, Ikenoue H, Shiroozu K, Sato K, Yoshinari M, et al. (1987) Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 65: 719\u2013723.","DOI":"10.1210\/jcem-65-4-719"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, et al. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47: 8\u201332.","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Al-Anazi KA, Inam S, Jeha MT, Judzewitch R (2005) Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer 13: 196\u2013198.","DOI":"10.1007\/s00520-004-0713-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Hyer SL, Newbold K, Harmer CL (2010) Early and late toxicity of radioiodine therapy: detection and management. Endocr Pract 16: 1064\u20131070.","DOI":"10.4158\/EP10170.RA"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Braverman LE, Woeber KA, Ingbar SH (1969) Induction of myxedema by iodide in patients euthyroid after radioiodine or surgical treatment of diffuse toxic goiter. N Engl J Med 281: 816\u2013821.","DOI":"10.1056\/NEJM196910092811504"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32 Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, et al. (2009) Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19: 559\u2013563.","DOI":"10.1089\/thy.2008.0364"},{"key":"33","unstructured":"33 Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, <i>et al.<\/i> (2019) Potassium iodide (KI) sensitive Graves\u2019 hyperthyroidism (GD). (2) Effective methylmercaptoimidazole (MMI) or radioactive iodine (RAI) therapy after escape. Thyroid 29 Suppl, A-121 (Abstract)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Sato K, Okamura K, Yoshinari M, Kuroda T, Ikenoue H, et al. (1992) Reversible primary hypothyroidism and elevated serum iodine level in patients with renal dysfunction. Acta Endocrinol (Copenh) 126: 253\u2013259.","DOI":"10.1530\/acta.0.1260253"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/7\/67_EJ20-0016\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T03:29:32Z","timestamp":1596252572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/7\/67_EJ20-0016\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0016","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}